The Predictors of COVID-19 Immunogenicity Elicited by Vaccines Against SARS-CoV-2 in Stem Cell Transplant Recipients
Makaleler > Tam Makale · 2024
Yazarlar: Umran Elbahr, Hakan Erdem, Handan Ankarali, Oğuz Reşat SİPAHİ, Jennie Pastrana, Chithra Vineeth, Suha Hejres, Leylagul Kaynar, Cigdem Pala Ozturk, Huseyin Abali, Nalan Babacan, Omar Sharif, Elias Fadel, Sara Bureshaid, Oğuz Reşat SİPAHİ
FLORA INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI, ESCI İndekslerine Giren Dergi, Uluslararası, Wos, 2024, cilt 29, ss 259-268
Özet
Introduction: The literature falls short in providing thorough investigations into the influence of COVID-19 vaccination among those undergoing hematopoietic stem cell transplantation (HSCT). Materials and Methods: This prospective study evaluates COVID-19 antibody levels in HSCT recipients. The HSCT patients, having undergone transplantation at least three months prior, received BNT162b2 mRNA, Gam-COVID-Vac adenoviral, or BBIBP-CorV inactivated vaccines. Blood samples were taken 2-24 weeks post second dose. Results: The study involved 28 participants, comprising nine allogeneic-HSCT and 19 autologous-HSCT recipients. Among them, 18 (64.2%) exhibited positive results in SARS-CoV-2 neutralizing antibody tests, occurring at a median of 10.5 weeks (ranging from 2 to 24 weeks). In multivariate logistic regression analysis, age and a higher Charlson Comorbidity Index emerged as statistically significant variables linked with suboptimal antibody responses. Interestingly, no significant disparities surfaced in terms of anti-SARSCoV-2 spike, SARS-CoV-2 (IgG + neutralizing) antibodies, and SARS-CoV-2 (neutralizing) antibodies titers across various vaccine types and transplantation modes. However, the anti-SARS-CoV-2 nucleocapsid titers demonstrated a significant increase in patients who received the BBIBP-CorV inactivated vaccine (Sinopharm, China). Moreover, within the non -vaccinated BMT subgroup, a slightly higher yet insignificant incidence of COVID-19 was observed in comparison to the vaccinated subgroup (2/28-7.1% vs. 3/11-27.2%, p= 0.125). During the six-month post -vaccination follow-up, COVID-19 incidence was 144.9 per 1000 patient -years in the vaccinated group, contrasting with 545.4 per 1000 patient -years in the unvaccinated group. Hence, a substantial vaccination efficacy of 73.4% was noted. No fatalities were reported among either vaccinated or unvaccinated HSCT patients who contracted COVID-19 during the 30 -day follow-up period. Conclusion: The inactivated vaccine demonstrated antibody responses comparable to the Pfizer-BioNTech vaccine.